Back to Search
Start Over
Targeting the PI3K signaling pathway in cancer.
- Source :
-
Current opinion in genetics & development [Curr Opin Genet Dev] 2010 Feb; Vol. 20 (1), pp. 87-90. Date of Electronic Publication: 2009 Dec 16. - Publication Year :
- 2010
-
Abstract
- The phosphoinositide 3-kinase (PI3K) pathway is activated in a variety of different human cancers, and inhibitors of this pathway are under active development as anti-cancer therapeutics. In this review, we discuss the data supporting the use of PI3K pathway inhibitors in genetically and clinically defined cancers. This review focuses on their efficacy as single agents and in combination with other targeted therapies, specifically those targeting the MEK-ERK signaling pathway.<br /> (Copyright 2009 Elsevier Ltd. All rights reserved.)
- Subjects :
- Antineoplastic Combined Chemotherapy Protocols therapeutic use
Humans
MAP Kinase Kinase Kinases
Phosphatidylinositol 3-Kinases genetics
Receptor, ErbB-2 antagonists & inhibitors
Signal Transduction drug effects
Antineoplastic Agents therapeutic use
Neoplasms drug therapy
Phosphoinositide-3 Kinase Inhibitors
Subjects
Details
- Language :
- English
- ISSN :
- 1879-0380
- Volume :
- 20
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Current opinion in genetics & development
- Publication Type :
- Academic Journal
- Accession number :
- 20006486
- Full Text :
- https://doi.org/10.1016/j.gde.2009.11.002